1型糖尿病延長試験 (T1DES)
This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D).
This observational study will:
- follow participants to determine how long they continue to produce insulin, and
- will also assess how changes in the immune system over time relate to the ability to produce insulin.
This information could help design better therapies for type 1 diabetes in the future.
調査の概要
詳細な説明
Depending upon a participant's level of insulin production, participation may be as short as one return visit or a maximum of five years. Evaluation visits will include:
- Overall health assessments
- Blood and urine collections
- Mixed meal tolerance test (MMTTs) for certain participants, per protocol.
研究の種類
入学 (推定)
連絡先と場所
研究場所
-
-
California
-
San Francisco、California、アメリカ、94143
- 募集
- UCSF School of Medicine
-
コンタクト:
- Rebecca Wesch
- 電話番号:415-476-5984
- メール:rebecca.wesch@ucsf.edu
-
主任研究者:
- Stephen Gitelman, MD
-
Stanford、California、アメリカ、94305
- 募集
- Stanford University
-
コンタクト:
- Trudy Esrey
- 電話番号:650-498-4450
- メール:tesrey@stanford.edu
-
主任研究者:
- Darrell Wilson, MD
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- 募集
- University of Colorado School of Medicine: Barbara Davis Center for Diabetes
-
主任研究者:
- Peter Gottlieb, MD
-
コンタクト:
- Mara Kinney
- 電話番号:(303) 724-8272
- メール:MARA.KINNEY@ucdenver.edu
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06519
- 完了
- Yale University
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- 引きこもった
- Emory University
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46202
- 募集
- Indiana University Riley Hospital for Children
-
コンタクト:
- Ellie Ryan
- 電話番号:317-278-7037
- メール:elmryan@iu.edu
-
コンタクト:
- Maria Spall
- 電話番号:317-278-7034
- メール:malnicho@iu.edu
-
主任研究者:
- Linda DiMeglio, MD, MPH
-
-
Iowa
-
Iowa City、Iowa、アメリカ、52242
- 募集
- University of Iowa Health Care Division of Pediatric Endocrinology
-
コンタクト:
- Joanne Cabbage
- 電話番号:319-356-4035
- メール:joanne-cabbage@uiowa.edu
-
主任研究者:
- Michael Tansey, MD
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- 募集
- Joslin Diabetes Center
-
コンタクト:
- Site Public Contact
- 電話番号:888-813-8669
- メール:T1DTrials@joslin.harvard.edu
-
主任研究者:
- Jason Gaglia, MD
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55454
- 募集
- University of Minnesota
-
コンタクト:
- Anne Street
- 電話番号:612-625-9709
- メール:stree065@umn.edu
-
主任研究者:
- Antoinette Moran, MD
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64108
- 完了
- Children's Mercy Hospital
-
-
South Dakota
-
Sioux Falls、South Dakota、アメリカ、57104
- 完了
- Sanford Research
-
-
Washington
-
Seattle、Washington、アメリカ、98101
- 募集
- Benaroya Research Institute
-
主任研究者:
- Sandra Lord, MD
-
コンタクト:
- Katie Bennett
- 電話番号:(206) 341-8945
- メール:kbennett@benaroyaresearch.org
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Former participants in Immune Tolerance Network (ITN) new-onset Type 1 Diabetes Mellitus (T1DM) studies with immunomodulatory agents as the intervention.
説明
Inclusion Criteria:
- Prior participant in an Immune Tolerance Network (ITN) executive committee approved T1DM study.
- Ability to sign informed consent/assent (as applicable for children).
Exclusion Criteria:
- Any medical condition that in the opinion of the principal investigator would interfere with safe completion of the trial; or
- Inability to comply with the study visit schedule and required assessments.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
|---|
|
Group 1: Detectable C-peptide by MMTT
Participants with detectable C-peptide at their:
Detectable C-peptide is defined as a value above the lower limit of detection. |
|
Group 2:Undetectable C-peptide by MMTT
Participants without detectable C-peptide at their:
Undetectable C-peptide is defined as a value below the lower limit of detection. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Beta Cell Function by MMTT-Stimulated Mean C-peptide Area Under the Curve (AUC)
時間枠:Baseline (Visit 0) to Month 60 (Year 5)
|
Evaluation of changes in beta cell function over time will be measured by mixed-meal tolerance test (MMTT) -Stimulated mean C-Peptide area under the curve (AUC). C-peptide is released by the pancreas into the bloodstream in equal amounts to insulin and reflects how much insulin pancreatic beta cells are making. The standardized MMTT evaluates whether beta cells are producing endogenous insulin. Detectable C-peptide is defined as any value during a MMTT of ≥0.15 ng/mL. |
Baseline (Visit 0) to Month 60 (Year 5)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Insulin Use in Units per Kilogram Body Weight Per Day
時間枠:Baseline (Visit 0) to Month 60 (Year 5)
|
The need to use exogenous insulin is an indication that the body is not producing enough endogenous insulin. Higher amounts of insulin use indicate higher disease activity. |
Baseline (Visit 0) to Month 60 (Year 5)
|
|
Change in HbA1C
時間枠:Baseline (Visit 0) to Month 60 (Year 5)
|
Glycosylated hemoglobin (HbA1c) is a measure of the average plasma concentration of blood sugar (glucose) over the previous three months and measures the level of optimal management of underlying disease. |
Baseline (Visit 0) to Month 60 (Year 5)
|
|
Count of Participant-Reported Major Hypoglycemic Events
時間枠:Baseline (Visit 0) to Month 60 (Year 5)
|
Major hypoglycemic events are defined as a glucose concentration <55 mg/dL (grades 2-5, NCI-CTCAE version 4.03), or clinically: involving seizure(s) or involving loss of consciousness (coma), or requiring assistance from another individual in order to recover. |
Baseline (Visit 0) to Month 60 (Year 5)
|
|
Time to Undetectable C-Peptide
時間枠:Baseline (Visit 0) to Month 60 (Year 5)
|
To assess the longevity of beta cell function, time to undetectable C-peptide will be evaluated using Kaplan-Meier survival estimates. |
Baseline (Visit 0) to Month 60 (Year 5)
|
|
Frequency of Grade 3 or Higher Adverse Events (AEs) of Interest
時間枠:Baseline (Visit 0) to Month 60 (Year 5)
|
Events of interest include but are not limited to:
Reference for Grade 3 or higher AEs: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03 (June 14, 2010). |
Baseline (Visit 0) to Month 60 (Year 5)
|
|
Severity of Grade 3 or Higher Adverse Events (AEs) of Interest
時間枠:Baseline (Visit 0) to Month 60 (Year 5)
|
Events of interest include but are not limited to:
Reference for Grade 3 or higher AEs: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03 (June 14, 2010). |
Baseline (Visit 0) to Month 60 (Year 5)
|
協力者と研究者
捜査官
- スタディチェア:Linda A. DiMeglio, MD, MPH,MA、Riley Hospital for Children at Indiana University Health
出版物と役立つリンク
一般刊行物
- Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA; AbATE Study Team. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013 Nov;62(11):3766-74. doi: 10.2337/db13-0345. Epub 2013 Jul 8.
- Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 2015 Aug 3;125(8):3285-96. doi: 10.1172/JCI81722. Epub 2015 Jul 20.
- Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR; T1DAL Study Team. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2013 Dec;1(4):284-94. doi: 10.1016/S2213-8587(13)70111-6. Epub 2013 Sep 23.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (推定)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- DAIT ITN066AI
- NIAID CRMS ID#: 20722 (その他の識別子:DAIT NIAID)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The plan is to share data in: 1.)ImmPort, a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts that also provides data analysis tools that are available to researchers who register online and subsequently receive DAIT approval; and 2.)TrialShare, a clinical trials research portal developed by the Immune Tolerance Network that makes data from the consortium's clinical trials publicly available without charge.
IPD 共有時間枠
After completion of the study.
IPD 共有アクセス基準
Will be available to the public.
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。